STOCK TITAN

NextCure: Ikarian reports 9.8% ownership stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

NextCure, Inc. (NXTC) is the issuer in an amended ownership report from Ikarian Capital, LLC and Neil Shahrestani. They report beneficial ownership of 500,282 shares, or 9.8%, with shared voting and dispositive power. Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts hold the securities; Ikarian Capital serves as investment manager to the Fund and sub-adviser to the accounts, and Shahrestani indirectly controls Ikarian Capital.

The 9.8% calculation uses a base of 5,079,305 shares, which includes 4,579,023 shares outstanding as of November 9, 2026, and 500,282 shares that may be acquired under warrants. Each reporting person states that the report is not an admission of beneficial ownership.

Reported beneficial ownership 500,282 shares Ikarian Capital, LLC and Neil Shahrestani reported shared voting and dispositive power.
Reported ownership percentage 9.8% Calculated using a base that includes shares acquirable under warrants.
Shares outstanding 4,579,023 shares As of November 9, 2026; used with warrant-acquirable shares in the reported percentage calculation.
Ownership calculation base 5,079,305 shares Includes 4,579,023 shares outstanding and 500,282 shares that may be acquired under warrants.
beneficial ownership technical
"may be deemed to have beneficial ownership of the securities covered by this statement"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
shared voting power technical
"Shared Voting Power 500,282.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared Dispositive Power 500,282.00"
separately managed accounts financial
"the Fund and certain separately managed accounts"
A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.
warrants financial
"shares that may be acquired by the Reporting Persons pursuant to warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NXTC shares did Ikarian Capital and Neil Shahrestani report?

They reported beneficial ownership of 500,282 shares, or 9.8%, with shared voting and dispositive power. The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.

How was the 9.8% NXTC ownership percentage calculated?

The calculation uses a base of 5,079,305 shares, including 4,579,023 shares outstanding as of November 9, 2026, and 500,282 shares that may be acquired under warrants.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





65343E207

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent common stock, $0.001 par value per share ("Common Stock") of NextCure, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 5,079,305 shares of Common Stock of the Issuer outstanding, which includes the 500,282 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 4,579,023 shares of Common Stock of the Issuer outstanding as of November 9, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the U.S. Securities and Exchange Commission (the "SEC") on November 10, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information. (2) The figure in Item 11 is based upon 5,079,305 shares of Common Stock of the Issuer outstanding, which includes the 500,282 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 4,579,023 shares of Common Stock of the Issuer outstanding as of November 9, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the SEC on November 10, 2026.


SCHEDULE 13G



Ikarian Capital, LLC
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani, Sole Manager
Date:11/16/2026
Neil Shahrestani
Signature:/s/ Neil Shahrestani
Name/Title:Neil Shahrestani
Date:11/16/2026
Exhibit Information

A Joint Filing Agreement is incorporated herein by reference to Exhibit 99.1 to the Schedule 13G filed on December 15, 2025 by the Reporting Persons with the SEC.

Keep reading